RxDoctor Payments Data

Brian Weaver, MD

Interventional Pain Medicine · Norfolk, VANPI 1104988328

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,534 of the $5,691 with a category attached, or 62.1%. 27 manufacturers reported payments, led by Abbott at 59.4% of the total. Reporting peaked in 2019 at $2,940 and has fallen 82.1% since, to $525 in 2025.

$5,691in general payments, 2019–2025

Across 158 payments — averaging $36.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Si-bone, Inc.$427
  • Assertio Therapeutics, Inc.$313
  • Almatica Pharma LLC$248
  • Globus Medical$210
  • Arbor Pharmaceuticals, Inc.$137
  • plus $976 from 21 others

What the payments were for

  • Travel & lodging$2,15638%
  • Food & beverage$3,53462%
  • Education$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,691 in reported general payments places this provider in the 55th percentile of 52 interventional pain medicine providers in Virginia.

See all interventional pain medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$1,344,501
Medicare patients
779
Services billed
85,739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen179$4,099
Gabapentin239$3,314
Tizanidine Hcl208$3,130
Pregabalin81$2,967
Lidocaine13$2,780
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen100$2,451
Celecoxib39$1,930
Metaxalone12$1,401
Cyclobenzaprine Hcl68$1,287
Tramadol Hcl130$1,075
Baclofen14$612
Methocarbamol28$422
Amitriptyline Hcl14$296
Meloxicam72$251
Oxycodone Hcl17$217

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →